PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.

Maria M Aivalioti Boris A Bartholdy Kith Pradhan Tushar D Bhagat Aliona Zintiridou Jong Jin Jeong Victor J Thiruthuvanathan Mario A Pujato Aditi Paranjpe Chi Zhang Ross L Levine Aaron D Viny Amittha Wickrema Amit K Verma Britta Will

Published in: Blood cancer discovery (2022)

We identify moderately impaired PU.1 mRNA expression as a biological modality predisposing Tet2-deficient hematopoietic stem and progenitor cells to malignant transformation. Our study furthermore uncovers a methylation-sensitive PU.1 gene network as a common feature of myeloid leukemia potentially allowing for the identification of patients at risk for malignant transformation. See related commentary by Schleicher and Pietras, p. 378. This article is highlighted in the In This Issue feature, p. 369.

Keyphrases

end stage renal disease
machine learning
acute myeloid leukemia
bone marrow
newly diagnosed
genome wide
ejection fraction
chronic kidney disease
deep learning
prognostic factors
dendritic cells
peritoneal dialysis
binding protein
immune response
copy number
patient reported outcomes
drug induced